Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of TQ-B3525 in Advanced Cancer
NCT03510767Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jun 2018
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQ-B3525 in lymphoma and solid tumor (advanced stage), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Dose-Limiting Toxicities at 28 days and Maximum Tolerated Dose at 28 days. Status: unknown.
02
Drugs
TQ-B3525
03
Conditions
lymphomasolid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03510767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03510767.